Evidence map›Paper›PMID 37612286›Full record

ArticleNature communications2023

A biallelic multiple nucleotide length polymorphism explains functional causality at 5p15.33 prostate cancer risk locus.

Sandor Spisak, Viktoria Tisza, Pier Vitale Nuzzo, Ji-Heui Seo, Balint Pataki, Dezso Ribli, Zsofia Sztupinszki, Connor Bell, Mersedeh Rohanizadegan, David R Stillman and 15 more

Erratum issuedOpen access · goldAbstract read
In one paragraph

Article in Nature communications, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. An erratum has been issued. Cited by 9 papers.

0numbers the graph read from it
0cells of the map it votes in
9citing papers in PubMed
4.1field-weighted citation impact, top 6% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

9 citing papers in PubMed, 13 citations in OpenAlex.

  1. Article
  2. Article
  3. Article
  4. Article
  5. Article
  6. Article
  7. Review
  8. Article
  9. Article
4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

25 authors at 8 institutions in 4 countries.

Sandor SpisakDepartment of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA, 02215, USA.ORCID http://orcid.org/0000-0002-7834-4642
Viktoria TiszaDepartment of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA, 02215, USA.
Pier Vitale NuzzoDepartment of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA, 02215, USA.ORCID http://orcid.org/0000-0002-5618-8079
Ji-Heui SeoDepartment of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA, 02215, USA.
Balint PatakiDepartment of Physics of Complex Systems, ELTE Eötvös Loránd University, Pázmány P. s. 1A, Budapest, 1117, Hungary.ORCID http://orcid.org/0000-0002-7974-5712
Dezso RibliDepartment of Physics of Complex Systems, ELTE Eötvös Loránd University, Pázmány P. s. 1A, Budapest, 1117, Hungary.ORCID http://orcid.org/0000-0002-2709-206X
Zsofia SztupinszkiComputational Health Informatics Program (CHIP) Boston Children's Hospital Harvard Medical School, Boston, MA, 02215, USA.
Connor BellDepartment of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA, 02215, USA.ORCID http://orcid.org/0000-0002-2148-2972
Mersedeh RohanizadeganDepartment of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA, 02215, USA.ORCID http://orcid.org/0000-0002-5636-7317
David R StillmanDepartment of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA, 02215, USA.
Sarah Abou AlaiwiDepartment of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA, 02215, USA.ORCID http://orcid.org/0000-0002-7073-3432
Alan H BartelsDepartment of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA, 02215, USA.
Marton PappInstitute of Enzymology, Research Centre for Natural Sciences, Budapest, 1117, Hungary.ORCID http://orcid.org/0000-0003-4975-253X
Anamay ShettyDepartment of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA, 02215, USA.
Forough AbbasiWomen's Cancer Program, Samuel Oschin Comprehensive Cancer Institute, Cedars-Sinai Medical Center, Los Angeles, CA, 90048, USA.
Xianzhi LinWomen's Cancer Program, Samuel Oschin Comprehensive Cancer Institute, Cedars-Sinai Medical Center, Los Angeles, CA, 90048, USA.ORCID http://orcid.org/0000-0001-9802-9896
Kate LawrensonWomen's Cancer Program, Samuel Oschin Comprehensive Cancer Institute, Cedars-Sinai Medical Center, Los Angeles, CA, 90048, USA.ORCID http://orcid.org/0000-0002-6469-2515
Simon A GaytherDivision of Gynecologic Oncology, Department of Obstetrics and Gynecology, Cedars-Sinai Medical Center, Los Angeles, CA, 90048, USA.ORCID http://orcid.org/0000-0001-7937-5443
Mark PomerantzDepartment of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA, 02215, USA.
Sylvan BacaDepartment of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA, 02215, USA.
Norbert SolymosiDepartment of Physics of Complex Systems, ELTE Eötvös Loránd University, Pázmány P. s. 1A, Budapest, 1117, Hungary.ORCID http://orcid.org/0000-0003-1783-2041
Istvan CsabaiDepartment of Physics of Complex Systems, ELTE Eötvös Loránd University, Pázmány P. s. 1A, Budapest, 1117, Hungary.ORCID http://orcid.org/0000-0001-9232-9898
Zoltan SzallasiComputational Health Informatics Program (CHIP) Boston Children's Hospital Harvard Medical School, Boston, MA, 02215, USA.ORCID http://orcid.org/0000-0001-5395-7509
Alexander GusevDepartment of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA, 02215, USA.ORCID http://orcid.org/0000-0002-7980-4620
Matthew L FreedmanDepartment of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA, 02215, USA. matthew_freedman@dfci.harvard.edu.ORCID http://orcid.org/0000-0002-0151-1238
Dana-Farber Cancer Institute · USCedars-Sinai Medical Center · USEötvös Loránd University · HUBroad Institute · USBoston Children's Hospital · USBrigham and Women's Hospital · USMagyar Agrár- és Élettudományi Egyetem · HUSemmelweis University · HU

Funding

Physician Scientist Training in Cancer ResearchT32CA009172 · NCI · DANA-FARBER CANCER INSTITUTE · PI Jennifer R Brown, James A. DeCaprio · 1985 to 2026
$17.1M
Weill Cornell Medicine (WCM) SPORE in Prostate CancerP50CA211024 · NCI · WEILL MEDICAL COLL OF CORNELL UNIV · PI LODA, MASSIMO · 2017 to 2021
$10.9M
Methods for Genome-wide Association Studies in Admixed PopulationsR01HG006399 · NHGRI · HARVARD UNIVERSITY D/B/A HARVARD SCHOOL OF PUBLIC HEALTH · PI PRICE, ALKES L · 2011 to 2024
$6.3M
Epidemiology and biology of lncRNAs in ovarian cancerR01CA207456 · NCI · H. LEE MOFFITT CANCER CTR & RES INST · PI GAYTHER, SIMON ANDREW, KANETSKY, PETER A · 2016 to 2020
$4.4M
(PQ3) A functional genomic approach to identification and interpretation of germline-tumor genetic interactionsR01CA227237 · NCI · DANA-FARBER CANCER INST · PI GUSEV, ALEXANDER, ZAITLEN, NOAH A · 2018 to 2022
$3.5M
Elucidation of the genetic mechanisms driving prostate tumorigenesis through integrative computational and functional approachesR01CA251555 · NCI · DANA-FARBER CANCER INST · PI FREEDMAN, MATTHEW L, PASANIUC, BOGDAN · 2021 to 2025
$3.4M
Elucidating prostate cancer risk mechanisms through large-scale cistrome wide association studiesR01CA262577 · NCI · DANA-FARBER CANCER INST · PI FREEDMAN, MATTHEW L, GIMELBRANT, ALEXANDER · 2022 to 2025
$3.3M
NCI NIH HHS P50 CA211024NCI NIH HHS R01 CA207456NCI NIH HHS R01 CA227237NCI NIH HHS R01 CA251555NCI NIH HHS R01 CA262577NCI NIH HHS T32 CA009172NHGRI NIH HHS R01 HG006399
6 · The paper itself

Abstract

To date, single-nucleotide polymorphisms (SNPs) have been the most intensively investigated class of polymorphisms in genome wide associations studies (GWAS), however, other classes such as insertion-deletion or multiple nucleotide length polymorphism (MNLPs) may also confer disease risk. Multiple reports have shown that the 5p15.33 prostate cancer risk region is a particularly strong expression quantitative trait locus (eQTL) for Iroquois Homeobox 4 (IRX4) transcripts. Here, we demonstrate using epigenome and genome editing that a biallelic (21 and 47 base pairs (bp)) MNLP is the causal variant regulating IRX4 transcript levels. In LNCaP prostate cancer cells (homozygous for the 21 bp short allele), a single copy knock-in of the 47 bp long allele potently alters the chromatin state, enabling de novo functional binding of the androgen receptor (AR) associated with increased chromatin accessibility, Histone 3 lysine 27 acetylation (H3K27ac), and ~3-fold upregulation of IRX4 expression. We further show that an MNLP is amongst the strongest candidate susceptibility variants at two additional prostate cancer risk loci. We estimated that at least 5% of prostate cancer risk loci could be explained by functional non-SNP causal variants, which may have broader implications for other cancers GWAS. More generally, our results underscore the importance of investigating other classes of inherited variation as causal mediators of human traits.

Indexed as

NeoplasmsPolymorphism, Single NucleotideAcetylationAllelesChromatinHumansMaleNucleotidesChromatinNucleotides

Identifiers

PMID37612286
PMCPMC10447552
OpenAlexW4386092780

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.